0B68 Lewis, Nancy L. - Thomas Jefferson University - Thomas Jefferson University
Dr. Lewis

Nancy L. Lewis, MD

Contact Dr. Lewis

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers
  2. Ontario's coloncancercheck: Results from canada's first province-wide colorectal cancer screening program
  3. Colonoscopy quality assurance in Ontario: Systematic review and clinical practice guideline
  4. Screening high-risk populations for lung cancer guideline recommendations
  5. A Phase i trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies
  6. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
  7. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors
  8. Epidemiology of Burkitt's lymphoma in Northwest Province, Cameroon, 2003-2010
  9. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
  10. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening
  11. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer
  12. Effective interventions to facilitate the uptake of breast, cervical and colorectal cancer screening: An implementation guideline
  13. What implementation interventions increase cancer screening rates? a systematic review
  14. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer
  15. Recruiting regional primary care leads for cancer care Ontario
  16. Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma
  17. Phase I pharmacologic and biologic study of ramucirumab (imc-1121b), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2
  18. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers
  19. Effects of food on the relative bioavailability of lapatinib in cancer patients
  20. The Effect of Stretching on Muscle Responses and Postural Sway Responses During Computerized Dynamic Posturography in Women and Men
0